Pricing of Keveyis

Mr B Elkington made this Freedom of Information request to Department of Health and Social Care

This request has been closed to new correspondence from the public body. Contact us if you think it ought be re-opened.

The request was partially successful.

Dear Department of Health,

You advised me early in March that you were holding discussions with Sun Pharma regarding the pricing of Keveyis, the only drug that has been authorised by the FDA for the treatment of Kypokolaemic Periodic Paralysis.

Pierre-Henri Coulon, the European Director Marketing informs me that France, Germany, Spain, Holland and Poland have all agreed to purchase Keveyis at a price of Eu5,700 a box of 100 tabs as they are aware that the market for this product is extremely limited.

Would you please let me know who in the DoH is leading these discussions or which dept is responsible for the discussions as Pierre-Henri is unaware that any discussions are currently taking place.

Yours faithfully,

Bryan Elkington

Do Not Reply,

1 Attachment

Dear Mr Elkington,

Please find attached the Department of Health's response to your recent
FOI request (our ref:  FOI 1083362) 

Yours sincerely,

 Alan Buchan 

Freedom of Information team
Department of Health


Please do not reply to this email. To contact the Department of Health,
please visit the Contact DH section on

show quoted sections

Incoming and outgoing e-mail messages are routinely monitored for
compliance with the Department of Health's policy on the use of electronic
communications. For more information on the Department of Health's e-mail
policy click here


This email was scanned by the Symantec virus scanning service and was
certified virus free.
Communications may be automatically logged, monitored and/or recorded for
legal purposes.